Wall Street Analysts See Johnson & Johnson (JNJ) as a Buy: Should You Invest?Zacks Investment Research • 10/13/26
Health Bellwether J&J Slumps As Middle East Conflict Hampers Medtech SalesInvestors Business Daily • 10/13/26
4 Dividend Kings Retirees Can Buy and Hold Forever: Safe Income for the Next 60 Years24/7 Wall Street • 10/13/26
Johnson & Johnson Hikes Earnings Guidance but Pharma Growth Masks a MedTech StumbleBarrons • 10/13/26
TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's diseasePRNewsWire • 10/12/26
New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroupsPRNewsWire • 10/12/26
Dow Jones Industrial Average Gets Spotlight: 5 Earnings Reports Representing 25% of ETF's Assets On DeckBenzinga • 10/12/26
Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 10/12/26
Treasury Bills vs Dividend Stocks: Which Income Stream Actually Fits Your Retirement24/7 Wall Street • 10/12/26
Johnson & Johnson and UnitedHealth Report the Same Morning. Here's What Matters.24/7 Wall Street • 10/12/26
Wells Fargo, Bank of America, Domino's, Johnson & Johnson, Inflation Data, and More to Watch This WeekBarrons • 10/11/26
New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasisPRNewsWire • 10/09/26
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 10/08/26
Big Yields Are Easy to Find. These 4 Dividend Stocks Have Something Better24/7 Wall Street • 10/08/26
Johnson & Johnson (JNJ) Q3 Earnings Preview: What You Should Know Beyond the Headline EstimatesZacks Investment Research • 10/08/26